Deep Brain Stimulation Devices Market Size, Share, Opportunities, And Trends By Product (Single Channel, Dual Channel), By Application (Pain Management, Epilepsy, Essential Tremor, Depression, Dystonia, Others), By End-Use (Hospitals, Neurology Clinics, Ambulatory Surgical Centers, Research Centers), And By Geography - Forecasts From 2023 To 2028

The deep brain stimulation devices market is estimated to grow at a CAGR of 8.91% during the forecast period.

Deep Brain Stimulation (DBS) devices are medical implants used to treat certain neurological and movement disorders by delivering electrical impulses to specific areas in the brain. These devices have been approved by regulatory authorities in various countries and have shown significant benefits in managing specific conditions. The rising prevalence of neurological disorders coupled with the growing elderly population and their higher risk rate is a major growth driver of the deep brain stimulation devices market. Moreover, technological advancements, government support through authority approvals, and increasing awareness for mental health prevention are further stimulating the deep brain stimulation devices market.

Increasing Prevalence of Neurological Disorders

The prevalence of neurological disorders, such as Parkinson's disease, essential tremor, and dystonia, has been rising globally. This rising prevalence is expected to bolster the deep brain stimulation devices market. For instance, in 2019, one in every eight individuals or 970 million people worldwide suffered from a mental condition with anxiety and depression being the most frequent as per the WHO report. Moreover, anxiety and depressive disorder rose by 26% and 28% respectively in just the first half of 2022 as per the same source. Globally, Parkinson's disease-related disability and mortality are growing faster than any other neurological condition.

Advancements in DBS Technology

Ongoing research and technological advancements have improved the safety and efficacy of DBS devices. Innovations in electrode design, stimulation parameters, and imaging techniques have led to better outcomes and fewer side effects thereby aiding the deep brain stimulation devices market. For example, advanced imaging techniques such as functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) have facilitated better targeting and electrode placement during DBS surgery. For instance, India Medtronic Private Limited launched the Percept™ PC Deep Brain Stimulation System in July 2021. The system is enabled with BrainSense™ Technology to capture brain signals while simultaneously delivering therapeutic stimulation.

Rapidly Aging Population

Parkinson's disease symptoms are frequent at the age of 60, according to the Parkinson's Foundation. Therefore, as the aging population increases, the incidence of these conditions is expected to grow creating a larger patient pool for DBS treatment. For instance, In 2020, the number of persons aged 60 and more exceeded the number of youngsters under the age of five and between 2015 and 2050, the fraction of the global population over the age of 60 will nearly double, from 12% to 22% according to the WHO. According to the World Health Organisation (WHO), epilepsy affects roughly 50 million people globally and is one of the most frequent neurological illnesses.

Increasing Awareness and Acceptance

Growing awareness and acceptance of DBS have been instrumental in increasing its adoption as a viable treatment option for certain neurological and movement disorders. This awareness coupled with the government approvals is contemplated to augment the deep brain stimulation devices market. For instance, the FDA granted Abbott Breakthrough Device Designation to examine the use of their deep brain stimulation (DBS) device in treatment-resistant depression (TRD) beginning in July 2022.  Moreover, the WHO Special Initiative for Mental Health (2019-23) advances mental health policy, advocacy, and human rights, as well as scales up quality interventions and services for people suffering from mental illnesses such as substance abuse and neurological diseases.

Restraints in the Market

The deep brain stimulation devices market has experienced growth and development however some restraints or challenges can impact its expansion. For example, DBS treatment involves the surgical implantation of the device, which can be costly. The initial cost includes the device itself, surgical procedures, hospital stays, and follow-up care. Additionally, ongoing maintenance and replacement of the device's battery can add to the long-term expenses. Additionally, in some cases, DBS stimulation can lead to adverse side effects, such as speech difficulties, gait disturbances, or cognitive changes. Finding the optimal stimulation settings may require trial and error, and some patients may not achieve satisfactory symptom control without intolerable side effects.

North America is Expected to Grow Considerably

North America is expected to hold a significant share of the deep brain stimulation devices market during the forecast period. The factors attributed to such a share are the rising aging population, higher prevalence of mental disorders, technological advancements and authority support. For instance, According to the Parkinson's Foundation, almost one million people in the United States will have Parkinson's disease by 2020. Men are 1.5 times more likely than women to suffer Parkinson's disease. Government support and approvals for DBS devices are further propelling the market expansion. For example, in January 2020, Abbott's Infinity DBS system got FDA clearance for the additional indication of Parkinson's disease from the US FDA.

Major Market Players

• Boston Scientific is headquartered in Marlborough, Massachusetts, USA. It was founded in 1979 and has grown to become a global leader in the medical device industry. It offers Vercise Genus™ Deep Brain Stimulation System which is the latest device developed by the company and granted FDA approval. It combines multiple independent current control, unique directional capabilities, and integrated visualization of patient anatomy.
• Cleveland Clinic is a renowned academic medical center based in Cleveland, USA. It is one of the leading medical institutions globally, known for its high-quality patient care, research, and medical education. Cleveland Clinic implanted the first SenSightTM Directional Lead System (Medtronic) for deep brain stimulation (DBS) for Parkinson's disease (PD), essential tremor, dystonia, and medically refractory epilepsy in August 2021. 

Key Market Developments

• In August 2022, Aster Medcity and India Medtronic joined forces to establish an extensive and state-of-the-art Deep Brain Stimulation (DBS) program in India, aimed at serving Parkinson's patients with advanced treatment options.
• In December 2021, Medtronic plc initiated the enrollment process for the first ADAPT-PD (Adaptive DBS Algorithm for Personalised Therapy in Parkinson's Disease) program. It was an experiment assessing the safety and effectiveness of adaptive deep brain stimulation (aDBS) in Parkinson's disease (PD) patients.
• In March 2021, Abbott announced the debut of NeuroSphere™ Virtual Clinic in the United States, a first-of-its-kind technology that allows patients to speak with clinicians, confirm optimal settings and operation, and obtain new treatment settings as needed remotely. The Food and Drug Administration of the United States has authorised it.

Segmentation:

• By Product
  • Single Channel
  • Dual Channel
• By Application
  • Pain Management
  • Epilepsy
  • Essential Tremor
  • Depression
  • Dystonia
  • Others
• By End-Use
  • Hospitals
  • Neurology Clinics
  • Ambulatory Surgical Centers
  • Research Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. DEEP BRAIN STIMULATION DEVICES MARKET, BY PRODUCT

5.1. Introduction

5.2. Single Channel

5.3. Dual Channel

6. DEEP BRAIN STIMULATION DEVICES MARKET, BY APPLICATION

6.1. Introduction

6.2. Pain Management

6.3. Epilepsy

6.4. Essential Tremor

6.5. Depression

6.6. Dystonia

6.7. Others

7. DEEP BRAIN STIMULATION DEVICES MARKET, BY END-USE

7.1. Introduction

7.2. Hospitals

7.3. Neurology Clinics

7.4. Ambulatory Surgical Centers

7.5. Research Centers

8. DEEP BRAIN STIMULATION DEVICES MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Boston Scientific

10.2. Medtronic

10.3. Abbott

10.4. Standford HealthCare

10.5. Cleveland Clinic

10.6. Mayo Clinic

10.7. Mayfield Clinic

10.8. John Hopkins Medicine

10.9. Medline Plus 

10.10. Aleva Neurotherapeutics

Boston Scientific

Medtronic

Abbott

Standford HealthCare

Cleveland Clinic

Mayo Clinic

Mayfield Clinic

John Hopkins Medicine

Medline Plus

Aleva Neurotherapeutics